A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD

References

• AlterP, MayerhoferB, KahnertK, et al. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2019;14:2163–2172. doi:10.2147/COPD.S20934331571852
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Published 2019 Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 214, 2020.
   Google Scholar
• FearyJR, RodriguesLC, SmithCJ, HubbardRB, GibsonJE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–962. doi:10.1136/thx.2009.12808220871122
   PubMed Web of Science ®Google Scholar
• CazzolaM, CalzettaL, BettoncelliG, et al. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med. 2012;106(2):249–256. doi:10.1016/j.rmed.2011.07.02121856140
   PubMed Web of Science ®Google Scholar
• CazzolaM, RoglianiP, MateraMG. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015;3(8):593–595. doi:10.1016/S2213-2600(15)00279-926208993
   PubMed Web of Science ®Google Scholar
• JanssenO, SchaumannF, HolzO, et al. Low-dose endotoxin inhalation in healthy volunteers-a challenge model for early clinical drug development. BMC Pulm Med. 2013;13(1):19. doi:10.1186/1471-2466-13-1923537365
   PubMed Web of Science ®Google Scholar
• HawkinsNM, HuangZ, PieperKS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11(3):292–298. doi:10.1093/eurjhf/hfp00119176539
   PubMed Web of Science ®Google Scholar
• SinDD, AnthonisenNR, SorianoJB, AgustiAG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–1257. doi:10.1183/09031936.0013380517138679
   PubMed Web of Science ®Google Scholar
• CazzolaM, ImperatoreF, SalzilloA, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998;114(2):411–415. doi:10.1378/chest.114.2.4119726723
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim International GmbH. Striverdi Respimat 2.5 microgram, solution for inhalation – summary of product characteristics, Europe. Published 2019 Available from: https://www.medicines.org.uk/emc/product/3255/smpc. Accessed 124, 2019.
   Google Scholar
• ChenY-F, ChengY-C, ChouC-H, ChenC-Y, YuC-J. Major comorbidities lead to the risk of adverse cardiovascular events in chronic obstructive pulmonary disease patients using inhaled long-acting bronchodilators: a case-control study. BMC Pulm Med. 2019;19(1):233. doi:10.1186/s12890-019-0999-z31795986
   PubMed Web of Science ®Google Scholar
• SalpeterSR, OrmistonTM, SalpeterEE. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest. 2004;125(6):2309–2321. doi:10.1378/chest.125.6.230915189956
   PubMed Web of Science ®Google Scholar
• AndreasS, BothnerU, TrampischM, HaenselM, BuhlR, AlterP. Effect of long-acting β2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. Pulm Pharmacol Ther. 2018;52:1–6. doi:10.1016/j.pupt.2018.08.00230077810
   PubMed Web of Science ®Google Scholar
• RabeKF, HurstJR, SuissaS. Cardiovascular disease and COPD: dangerous liaisons? Eur Respir Rev. 2018;27(149):pii:180057. doi:10.1183/16000617.0057-2018
   PubMed Web of Science ®Google Scholar
• MateraMG, OraJ, CazzolaM. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. Ther Clin Risk Manag. 2015;11:1805–1811. doi:10.2147/TCRM.S7358126676161
   PubMed Web of Science ®Google Scholar
• HandleyDA, MorleyJ. The pursuit of precision pharmaceuticals: divergent effects of β2 agonist isomers. Expert Opin Investig Drugs. 1998;7(10):1601–1616. doi:10.1517/13543784.7.10.1601
   PubMedGoogle Scholar
• RamsayCM, CowanJ, FlanneryE, McLachlanC, TaylorDR. Bronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthma. Eur J Clin Pharmacol. 1999;55(5):353–359. doi:10.1007/s00228005064010456484
   PubMed Web of Science ®Google Scholar
• FergusonGT, FeldmanGJ, HofbauerP, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–645. doi:10.2147/COPD.S6171724966672
   PubMed Web of Science ®Google Scholar
• KochA, PizzichiniE, HamiltonA, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714. doi:10.2147/COPD.S6250225045258
   PubMed Web of Science ®Google Scholar
• McGarveyL, NiewoehnerD, MagderS, et al. One-year safety of olodaterol once daily via Respimat® in patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysis. COPD. 2015;12(5):484–493. doi:10.3109/15412555.2014.99186425692310
   PubMedGoogle Scholar
• AlterP, WatzH, KahnertK, et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med. 2018;137:14–22. doi:10.1016/j.rmed.2018.02.01129605197
   PubMed Web of Science ®Google Scholar
• WatzH, WaschkiB, MeyerT, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010;138(1):32–38. doi:10.1378/chest.09-281020190002
   PubMed Web of Science ®Google Scholar
• HohlfeldJM, Vogel-ClaussenJ, BillerH, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018;6(5):368–378. doi:10.1016/S2213-2600(18)30054-729477448
   PubMed Web of Science ®Google Scholar
• RaupachT, BahrF, HerrmannP, et al. Slow breathing reduces sympathoexcitation in COPD. Eur Respir J. 2008;32(2):387–392. doi:10.1183/09031936.0010960718385175
   PubMed Web of Science ®Google Scholar
• MaltaisF, O’DonnellD, Galdiz IturriJB, et al. Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2018;12:1–13. doi:10.1177/1753465818755091
   Web of Science ®Google Scholar
• BertonDC, BarbosaPB, TakaraLS, et al. Bronchodilators accelerate the dynamics of muscle O2 delivery and utilisation during exercise in COPD. Thorax. 2010;65(7):588–593. doi:10.1136/thx.2009.12085720627914
   PubMed Web of Science ®Google Scholar
• LahousseL, VerhammeKM, StrickerBH, BrusselleGG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):149–164. doi:10.1016/S2213-2600(15)00518-426794033
   PubMed Web of Science ®Google Scholar
• GalliA, AmbrosiniF, LombardiF. Holter monitoring and loop recorders: from research to clinical practice. Arrhythm Electrophysiol Rev. 2016;5(2):136–143. doi:10.15420/AER.2016.17.227617093
   PubMedGoogle Scholar
• PrioriSG, Blomström-LundqvistC, MazzantiA, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). EP Europace. 2015;17(11):1601–1687. doi:10.1093/europace/euv31926318695
   PubMed Web of Science ®Google Scholar
• IncorvaiaC, MontagniM, MakriE, Riario-SforzaGG, RidoloE. Striving for optimal bronchodilation: focus on olodaterol. Int J Chron Obstruct Pulmon Dis. 2016;11:439–444. doi:10.2147/COPD.S9607027042036
   PubMed Web of Science ®Google Scholar
• WatzH, TroostersT, BeehKM, et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545–2558. doi:10.2147/COPD.S14348828883722
   PubMed Web of Science ®Google Scholar
• NelsonHS, GrossNJ, LevineB, et al. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007;29(10):2167–2178. doi:10.1016/j.clinthera.2007.10.00718042473
   PubMed Web of Science ®Google Scholar
• BorghardtJM, KloftC, SharmaA. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018:2732017. doi:10.1155/2018/273201730018677
   PubMed Web of Science ®Google Scholar
• BouyssouT, HoenkeC, RudolfK, et al. Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010;20(4):1410–1414. doi:10.1016/j.bmcl.2009.12.08720096576
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMR, BeckE, HamiltonAL, KorduckiL, KokerP, FogartyC. A randomised, placebo-controlled, phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109(5):596–605. doi:10.1016/j.rmed.2015.02.01225829298
   PubMed Web of Science ®Google Scholar
• WangM-T, LiouJ-T, LinCW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. 2018;178(2):229–238. doi:10.1001/jamainternmed.2017.772029297057
   PubMed Web of Science ®Google Scholar